IMPORTANCE Black and Hispanic patients are less likely than white patients to use oral anticoagulants for atrial fibrillation. Little is known about racial/ethnic differences in use of direct-acting oral anticoagulants (DOACs) for atrial fibrillation.
A trial fibrillation (AF) is the most common heart rhythm disorder in the United States and a significant risk factor for ischemic stroke. [1] [2] [3] [4] Long-term oral anticoagulant therapy (OAC) can reduce the stroke risk attributable to AF. 5, 6 While the prevalence of AF is lower in black individuals, they face a higher risk of stroke. [7] [8] [9] Similarly, the prevalence of AF is lower in Hispanic patients but with poorer outcomes observed compared with white patients with AF.
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Prior studies have shown that anticoagulation use in underrepresented ethnic groups with AF is lower than in white individuals, with some of this disparity explained by socioeconomic status. 13, 14 Time in the therapeutic range (TTR) of international normalized ratio (INR) of 2.0 to 3.0 on warfarin, a measure of anticoagulation quality, has also been shown to be lower in black patients compared with white patients, as well as in patients with limited English proficiency, increasing the stroke risk in these populations. 15, 16 However, these studies did not examine whether these differences in AF care extended to the use of direct-acting oral anticoagulants (DOACs).
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We assessed contemporary racial/ethnic disparities in the use of warfarin and DOACs for patients with AF in the USbased Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). The objectives of our analysis were to determine the rates of warfarin and DOAC use in patients with AF by race/ethnicity, assess the appropriateness of anticoagulant use by race/ethnicity per standard guidelines based on patients' CHA 2 DS 2 -VASc scores, 21 and examine anticoagulant quality and persistence by race/ethnicity.
Methods

Study Design
The rationale, design, and methods of the ORBIT-AF II registry have been published previously. 22 Briefly, ORBIT-AF II is a prospective, multicenter, US-based registry of outpatients with AF. Patients were enrolled at 244 sites by various health care professionals, including primary care physicians, general cardiologists, and electrophysiologists. The ORBIT-AF II study only enrolled patients who either had a new diagnosis of AF within the prior 6 months or started receiving a DOAC for AF within the prior 3 months. The ORBIT-AF I cohort was not used in the current analysis since it preceded widespread use of DOAC medications. 23 Eligible patients were those 21 years or older with electrocardiographically documented AF. Patients with transient AF owing to a reversible cause (eg, postoperative status), solitary atrial flutter without AF, or an estimated life expectancy of less than 6 months were excluded. A web-based case report form was used to collect patient demographics, medical history, medications, vital signs, laboratory data (including INR tests), imaging, and electrocardiographic parameters. Changes in pharmacotherapy, cardiac rhythm, and subsequent cardiovascular events and procedures were documented in follow-up. Participants in the ORBIT-AF II study provided written informed consent, and sites received regulatory board approval for this study pursuant to local regulations. The study was coordinated by the Duke Clinical Research Institute and approved by the Duke University Institutional Review Board.
Study Population
Between February 2013 and July 2016, the registry enrolled 13 404 patients. Follow-up occurred at 6-month intervals and lasted 12 to 24 months, depending on enrollment date. At baseline, patients were asked to identify their race and ethnicity. Racial/ethnic groups were treated as mutually exclusive. For the present analysis, patients who selected identifiers other than "White," "Black/African American," or "Hispanic/ Latino" at intake were excluded. We also excluded patients without any available follow-up information.
Statistical Analysis
Use of anticoagulants at the index ORBIT-II enrollment visit and other baseline characteristics were compared across race/ ethnicity. Categorical variables are presented as frequencies and percentages, with differences between groups assessed by the χ 2 test. Continuous variables are presented as median (interquartile range [IQR] ) with differences between groups assessed by the Kruskal-Wallis test. Racial/ethnic comparisons of percentages of any anticoagulant use, warfarin use, and DOAC use overall and in groups stratified by CHA 2 DS 2 -VASc scores (an index composed of points for congestive heart failure; hypertension; age ≥75 years; diabetes mellitus; prior stroke, transient ischemic attack, or thromboembolism; vascular disease; age 65-74 years; and sex category [female]) less than 2 or 2 or greater were assessed by the χ 2 test. A multivariable logistic regression model with site as a random effect was used to evaluate the association between race/ethnicity and overall OAC use at baseline. The same model strategy was repeated for the association between race/ethnicity and DOAC use at baseline among patients on any OAC. The white racial group served as the reference group. Continuous variables, nonlinear with respect to the outcome, were fit with linear splines. The model was adjusted for patient characteristics that might explain the association between race/ethnicity and outcomes, including clinical characteristics (eg, medical
Key Points
Question Are there racial/ethnic differences in the use of oral anticoagulants, particularly direct-acting oral anticoagulants, in patients with atrial fibrillation?
Findings In this multicenter US-based registry study of a cohort of 12 147 outpatients with atrial fibrillation, black patients were significantly less likely to receive direct-acting oral anticoagulants than white patients, even after controlling for clinical and sociodemographic features; no difference between white patients and Hispanic patients was observed.
Meaning Reducing disparities in stroke prevention for patients with atrial fibrillation may improve overall quality of care and result in reduced complication rates. The discontinuation of OAC medications was defined as a report of discontinuation of OAC with a discontinuation date and a patient's receiving no OAC at the following visit. This definition minimizes discontinuations that are temporary. Time to discontinuation is displayed via a Kaplan-Meier plot. A Cox frailty model, with a random effect for site, was used to evaluate the association between race/ethnicity and OAC discontinuation before and after adjustment for potential confounders. Associations are presented as hazard ratios, 95% CIs, and
We assessed quality of warfarin anticoagulation by TTR as calculated from the first INR to the last INR available, using the Rosendaal method. 24 Any inter-INR test gaps greater than 8 weeks (ie, 56 days) were excluded. The median TTR length during follow-up was compared across groups with the Kruskal-Wallis test. For patients receiving DOACs at baseline, quality was assessed by whether the dose prescribed matched the US Food and Drug Administration label for each patient, given the patient's age, weight, renal function, and concomitant medications, as previously described. 22 The percentage of patients classified as appropriately dosed was compared across race/ethnicity by the χ 2 test.
Statistical analyses were performed using SAS version 9.4 (SAS Institute), and 2-tailed P values <.05 were considered significant for all statistical tests. Data analysis occurred from February 2017 to February 2018.
Results
The baseline ORBIT-AF II population included 13 404 patients enrolled at 244 sites from February 2013 to July 2016. For this analysis, we excluded 546 patients who identified as races/ethnicities other than white, black, or Hispanic. We also excluded 1 patient who was taking more than 1 anticoagulant and 440 patients without any follow-up information. This yielded a study cohort of 12 417 patients, including 9166 patients with newly diagnosed AF (within 6 months of study entry). A total of 8572 of 12 417 patients (69.0%) were enrolled by general cardiologists, 2806 of 12 417 (22.6%) by electrophysiologists, and 942 of 12 417 (7.6%) by internists or primary care clinicians. Within this cohort, 11 100 patients (89.4%) were white, 646 (5.2%) were black, and 671 (5.4%) were Hispanic ( Table 1) .
Relative to white patients and Hispanic patients, black patients were significantly younger (median [ Physicians reported contraindications to oral anticoagulant therapy (including high bleeding risk, frequent falls, and frailty). The proportion with contraindications did not differ by race/ethnicity (Table 1) .
Overall OAC use, either with warfarin or DOACs, was high, with 9865 of 11 100 white patients (88.9%), 544 of 646 black patients (84.2%), and 586 of 671 Hispanic patients (87.3%) reporting taking any OAC ( Table 2 ). The unadjusted OR for any anticoagulant use among black patients com-pared with white patients was 0.71 (95% CI, 0.56-0.90). After adjusting for baseline clinical features, the OR increased modestly to 0.75 (95% CI, 0.56-0.99) ( Among patients receiving any OAC, DOACs were used more frequently than warfarin and differences between black patients and white patients were more clearly evident; the unadjusted OR was 0.60 (95% CI, 0.46-0.77). After adjustment for clinical features, the aOR was 0.63 (95% CI, 0.49-0.83) ( 
Adjusting for Socioeconomic Status
Additional adjusting for level of education, median household income by zip code, and insurance type, the markers of socioeconomic status, as well as region, produced a small change in the OR of use of any anticoagulant by black patients or white patients, but the value was no longer significant (aOR, 0.78 [95% CI, 0.59-1.04]; Table 2 ). (Complete re- 
Anticoagulation Quality and Persistence
The study cohort included 1704 patients with AF who were treated with warfarin. The median number of INR tests during the follow-up period for patients taking warfarin for whom a TTR could be calculated (ie, those having at least 2 INR tests) was 18 (IQR, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] The time to discontinuation of anticoagulation was similar across racial/ethnic groups (eFigure in the Supplement). After adjusting for patient sociodemographic and clinical factors, the adjusted hazard ratio for discontinuing anticoagulant therapy was 0.88 (95% CI, 0.70-1.12) for black patients and 0.99 (95% CI, 0.79-1.25) for Hispanic patients compared with white patients.
Discussion
Anticoagulation is standard therapy for patients with AF who are at increased stroke risk. Racial and ethnic disparities in anticoagulant use have been described previously.
25,26 However, few studies have explored racial/ethnic disparities in the use of DOACs by patients with AF. We examined the association between race/ethnicity and the use of any OAC, and specifically DOACs, in patients with AF in the ORBIT-AF II registry. There are several notable findings from this analysis. First, although OAC use was high in the ORBIT-AF II registry, black patients were less likely to use any OAC than white patients and were particularly less likely to use DOACs. Hispanic patients, however, had similar treatment rates with any OAC and DOACs as white patients. Second, while we expected to see the difference in race mediated by socioeconomic status, differences between black and white patients largely persisted despite inclusion of socioeconomic markers in our statistical models. Third, anticoagulation quality was poorer in black patients and Hispanic patients, with lower overall TTR and lower rates of appropriate DOAC dosing. Lastly, rates of discontinuation of OAC were similar across races/ethnicities. greater for white patients than for nonwhite patients with AF (95% CI, 1.09-1.32), but this study only included patients who were hospitalized with stroke. Using a random sample of Medicare beneficiaries newly diagnosed with AF, researchers found that black race was significantly associated with a lower odds of receiving DOACs (ie, dabigatran and rivaroxaban) compared with receiving warfarin. 29 The study period for this report from Medicare concluded on December 31, 2012, and was thus unlikely to represent current DOAC usage patterns. The earlier ORBIT-AF I registry also observed differences in anticoagulant use and treatment quality by race/ethnicity. 30 However, the ORBIT-AF I study was unable to assess contemporary use of DOAC medications. Additionally, none of these studies included detailed data on INR measures and DOAC dosing, as the present analysis does. There have been several possible reasons proposed to explain racial/ethnic disparities in AF management. First, limited access to specialists in minority populations has been described and remains an important target of interventions to reduce disparities. 31 In our study, a higher percentage of black patients and Hispanic patients than white patients were enrolled by primary care physicians. While we observed that internal medicine and primary care clinicians were less likely to prescribe DOACs than cardiologists and electrophysiologists, our results were adjusted for clinician type (eTables 1 and 2 in the Supplement). Second, out-of-pocket costs for DOACs may be a greater barrier to their use among patients in lower socioeconomic brackets. Adjustment for socioeconomic status did not substantially reduce the racial differences in our results, but our control for economic determinants is incomplete. Others have also highlighted the roles of health literacy, patient perceptions, patient adherence, implicit bias, and trust in medical care as additional explanations of racial/ethnic disparities in care. 16, [32] [33] [34] [35] This study cannot address these latter features.
Detailed assessment of the respective roles and preferences of patients and physicians in the anticoagulation decision is merited. Notably, we found that increased rates of OAC use among white patients extended to patients with CHA 2 DS 2 -VASc scores less than 2, a group at low risk of stroke in which there may be little net benefit of OACs. Such possible overuse is consistent with other observations of potentially harmful medical overuse among individuals of higher socioeconomic status in the United States. 36 While racial/ethnic disparities are usually marked by underuse, overuse in racial/ethnic majority populations is another reasonable target for quality improvement initiatives.
As we and others have shown, the quality of warfarin treatment is lower in racial/ethnic minority patients than white patients, and poor TTR is associated with increased stroke risk. 37, 38 Further, black patients with AF were less likely to receive DOACs, which are easier to use than warfarin and likely safer. 39, 40 Recent evidence has shown that medication adherence is higher for DOACs than for warfarin. 41 This increase in adherence to DOACs over warfarin may serve as a way to improve anticoagulant treatment in racial/ethnic minority patients with AF. Our findings are particularly notable given this population's access to health care (ie, all included patients were recruited from medical clinics). This analysis has several strengths. It is, to our knowledge one of the first studies to compare baseline use of DOACs by race/ethnicity as well as the quality of DOAC use. The data were obtained from a prospectively assembled registry with detailed clinical information and close follow-up, thereby avoiding pitfalls of alternative designs, such as administrative database analyses.
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Limitations
There are also potential limitations to our analyses. First, because this was an observational study, we cannot exclude the possibility of residual or unmeasured confounding. Second, there can be concerns about the representativeness of patients enrolled in registries. The ORBIT-AF II registry sought recruitment sites throughout the United States, but investigator participation was voluntary, and patients had to agree to enter the study through the informed consent process. 43 These aspects of study design may raise concerns whether these findings apply to the broad population of patients with AF. 44 The proportion of patients in the ORBIT-AF II registry overall who were taking anticoagulants was 89%, higher than that reported from cohorts that were less selective. For example, a recent claims-based study from the Veterans' Administration reported 63% of patients with AF were taking anticoagulants.
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Similarly, the overall average TTR of patients taking warfarin in the ORBIT-AF II registry, 67%, is higher than the average TTR of 56% reported by the Veteran's Administration. 25 However, despite these higher overall
indices of anticoagulation quality, we still observed clear racial disparities in use of anticoagulants in the ORBIT-AF II registry. Notably, the difference between black patients and white patients in TTR in this study (−10%) was very similar to the difference observed in the VA study (−8%). 25 As a result, the racial disparities we report appear to be more broadly generalizable. A third limitation of our analyses is the reduced statistical power of some racial/ethnic comparisons. This issue is common in studies of AF, owing to the overall lower prevalence of AF in racial/ethnic minority populations along with limited representation of such minorities in clinical trials and registries. 45 Fourth, patients in the ORBIT-AF II registry were preferentially selected if they were starting a DOAC. This sampling feature increased the proportion using DOACs but still allowed evaluation of racial and ethnic differences in the use of these anticoagulants. Lastly, our measures of socioeconomic status were limited and measures such as zip-code level income may not have fully characterized an individual's socioeconomic status.
Conclusions
In the ORBIT-AF II registry of patients with AF, we found reduced use of OAC therapy in black patients compared with white patients and Hispanic patients. These differences persisted after controlling for socioeconomic markers and region. The effect was particularly pronounced for DOAC use. We also found that anticoagulation quality in black patients and Hispanic patients was inferior to that that in white patients, with lower TTR values in those taking warfarin and modestly greater underdosing in patients taking DOACs. These results contribute toward understanding racial/ethnic differences in stroke-preventive treatment in patients with AF. Novel approaches are needed to address modifiable causes of racial/ethnic disparities in anticoagulant use, a central issue in improving the overall quality of care for patients with AF. 
